STOCK TITAN

[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Kineta (KA) filed a Form 4 disclosing that director Shawn Iadonato exercised 237,500 stock options on 06/23/2025 at strike prices of $0.36 and $0.611, actions triggered by full vesting upon shareholder approval of the TuHURA Biosciences merger.

To cover taxes, 52,353 shares were sold at $0.26 (Code F). Net of the sale, his direct holdings rose to 860,377 shares; combined with 8,553 shares held via an IRA, total beneficial ownership is 868,930 shares, a ~27% increase.

The transactions were contractual (Code M) rather than open-market purchases, signalling alignment but offering limited insight into insider sentiment.

Kineta (KA) ha presentato un Modulo 4 comunicando che il direttore Shawn Iadonato ha esercitato 237.500 opzioni azionarie il 23/06/2025 a prezzi di esercizio di 0,36$ e 0,611$, operazioni attivate dal pieno maturamento in seguito all'approvazione da parte degli azionisti della fusione con TuHURA Biosciences.

Per coprire le tasse, sono state vendute 52.353 azioni a 0,26$ (Codice F). Al netto della vendita, le sue partecipazioni dirette sono salite a 860.377 azioni; insieme a 8.553 azioni detenute tramite un IRA, la proprietà totale effettiva ammonta a 868.930 azioni, con un incremento di circa il 27%.

Le transazioni erano contrattuali (Codice M) e non acquisti sul mercato aperto, indicando un allineamento ma fornendo informazioni limitate sul sentiment interno.

Kineta (KA) presentó un Formulario 4 revelando que el director Shawn Iadonato ejerció 237,500 opciones sobre acciones el 23/06/2025 a precios de ejercicio de $0.36 y $0.611, acciones desencadenadas por la consolidación total tras la aprobación de los accionistas de la fusión con TuHURA Biosciences.

Para cubrir impuestos, se vendieron 52,353 acciones a $0.26 (Código F). Después de la venta, sus participaciones directas aumentaron a 860,377 acciones; combinado con 8,553 acciones mantenidas a través de una IRA, la propiedad total beneficiosa es de 868,930 acciones, un aumento de aproximadamente el 27%.

Las transacciones fueron contractuales (Código M) en lugar de compras en el mercado abierto, señalando alineación pero ofreciendo poca información sobre el sentimiento interno.

Kineta (KA)는 이사 Shawn Iadonato가 2025년 6월 23일에 행사 가격이 각각 $0.36과 $0.611인 237,500 주식 옵션을 행사했다고 Form 4를 통해 공시했습니다. 이 행위는 TuHURA Biosciences 합병에 대한 주주 승인으로 인한 완전 권리 확정에 따른 것입니다.

세금 부담을 위해 52,353 주식이 $0.26에 매도되었습니다(코드 F). 매도 후 그의 직접 보유 주식은 860,377 주로 증가했으며, IRA를 통해 보유한 8,553 주를 합하면 총 실질 소유 주식은 868,930 주로 약 27% 증가했습니다.

이 거래는 공개 시장 매수가 아닌 계약에 따른 것이며(코드 M), 내부자와의 이해관계 일치를 나타내지만 내부자의 심리 상태에 대한 정보는 제한적입니다.

Kineta (KA) a déposé un Formulaire 4 révélant que le directeur Shawn Iadonato a exercé 237 500 options d'achat d'actions le 23/06/2025 à des prix d'exercice de 0,36 $ et 0,611 $, des actions déclenchées par l'acquisition complète suite à l'approbation des actionnaires de la fusion avec TuHURA Biosciences.

Pour couvrir les impôts, 52 353 actions ont été vendues à 0,26 $ (Code F). Après cette vente, ses participations directes ont augmenté à 860 377 actions ; combinées avec 8 553 actions détenues via un IRA, la propriété bénéficiaire totale s'élève à 868 930 actions, soit une augmentation d'environ 27 %.

Les transactions étaient contractuelles (Code M) plutôt que des achats sur le marché ouvert, signalant un alignement mais offrant une vision limitée du sentiment des initiés.

Kineta (KA) reichte ein Formular 4 ein und gab bekannt, dass Direktor Shawn Iadonato am 23.06.2025 237.500 Aktienoptionen zu Ausübungspreisen von 0,36$ und 0,611$ ausgeübt hat. Diese Aktionen wurden durch die vollständige Vesting nach der Zustimmung der Aktionäre zur Fusion mit TuHURA Biosciences ausgelöst.

Zur Deckung der Steuern wurden 52.353 Aktien zum Preis von 0,26$ verkauft (Code F). Nach dem Verkauf stieg sein direkter Aktienbestand auf 860.377 Aktien; zusammen mit 8.553 über ein IRA gehaltenen Aktien beträgt das gesamte wirtschaftliche Eigentum 868.930 Aktien, ein Anstieg von etwa 27%.

Die Transaktionen waren vertraglich bedingt (Code M) und keine Käufe am offenen Markt, was auf eine Übereinstimmung hinweist, jedoch nur begrenzte Einblicke in die Stimmung der Insider bietet.

Positive
  • Director’s direct ownership increased by 185,147 shares (net), a ~27 % rise, improving insider-shareholder alignment post-merger.
Negative
  • A 52,353-share sale (≈6 % of newly issued shares) at $0.26 for tax withholding marginally offsets the ownership increase.

Insights

TL;DR: Option exercise lifts insider stake 27%, but merger-driven and neutral for valuation.

The bulk of the activity—225 k options at $0.36 and 12.5 k at $0.611—was automatically exercised once the TuHURA merger terms cleared, eliminating those options and adding 237.5 k shares to float. Only 52.4 k shares (≈6% of new shares) were sold for tax withholding, so most of the stock was retained, lifting Iadonato’s direct ownership to 860.4 k shares. While the 27% stake increase exceeds the 5 % materiality threshold for insider holdings, the lack of open-market buying tempers bullish interpretation. No cash proceeds to Kineta arise from the option exercise because strikes were minimal. Overall impact on share supply, governance control, and liquidity is modest, leaving the filing neutral for near-term valuation.

Kineta (KA) ha presentato un Modulo 4 comunicando che il direttore Shawn Iadonato ha esercitato 237.500 opzioni azionarie il 23/06/2025 a prezzi di esercizio di 0,36$ e 0,611$, operazioni attivate dal pieno maturamento in seguito all'approvazione da parte degli azionisti della fusione con TuHURA Biosciences.

Per coprire le tasse, sono state vendute 52.353 azioni a 0,26$ (Codice F). Al netto della vendita, le sue partecipazioni dirette sono salite a 860.377 azioni; insieme a 8.553 azioni detenute tramite un IRA, la proprietà totale effettiva ammonta a 868.930 azioni, con un incremento di circa il 27%.

Le transazioni erano contrattuali (Codice M) e non acquisti sul mercato aperto, indicando un allineamento ma fornendo informazioni limitate sul sentiment interno.

Kineta (KA) presentó un Formulario 4 revelando que el director Shawn Iadonato ejerció 237,500 opciones sobre acciones el 23/06/2025 a precios de ejercicio de $0.36 y $0.611, acciones desencadenadas por la consolidación total tras la aprobación de los accionistas de la fusión con TuHURA Biosciences.

Para cubrir impuestos, se vendieron 52,353 acciones a $0.26 (Código F). Después de la venta, sus participaciones directas aumentaron a 860,377 acciones; combinado con 8,553 acciones mantenidas a través de una IRA, la propiedad total beneficiosa es de 868,930 acciones, un aumento de aproximadamente el 27%.

Las transacciones fueron contractuales (Código M) en lugar de compras en el mercado abierto, señalando alineación pero ofreciendo poca información sobre el sentimiento interno.

Kineta (KA)는 이사 Shawn Iadonato가 2025년 6월 23일에 행사 가격이 각각 $0.36과 $0.611인 237,500 주식 옵션을 행사했다고 Form 4를 통해 공시했습니다. 이 행위는 TuHURA Biosciences 합병에 대한 주주 승인으로 인한 완전 권리 확정에 따른 것입니다.

세금 부담을 위해 52,353 주식이 $0.26에 매도되었습니다(코드 F). 매도 후 그의 직접 보유 주식은 860,377 주로 증가했으며, IRA를 통해 보유한 8,553 주를 합하면 총 실질 소유 주식은 868,930 주로 약 27% 증가했습니다.

이 거래는 공개 시장 매수가 아닌 계약에 따른 것이며(코드 M), 내부자와의 이해관계 일치를 나타내지만 내부자의 심리 상태에 대한 정보는 제한적입니다.

Kineta (KA) a déposé un Formulaire 4 révélant que le directeur Shawn Iadonato a exercé 237 500 options d'achat d'actions le 23/06/2025 à des prix d'exercice de 0,36 $ et 0,611 $, des actions déclenchées par l'acquisition complète suite à l'approbation des actionnaires de la fusion avec TuHURA Biosciences.

Pour couvrir les impôts, 52 353 actions ont été vendues à 0,26 $ (Code F). Après cette vente, ses participations directes ont augmenté à 860 377 actions ; combinées avec 8 553 actions détenues via un IRA, la propriété bénéficiaire totale s'élève à 868 930 actions, soit une augmentation d'environ 27 %.

Les transactions étaient contractuelles (Code M) plutôt que des achats sur le marché ouvert, signalant un alignement mais offrant une vision limitée du sentiment des initiés.

Kineta (KA) reichte ein Formular 4 ein und gab bekannt, dass Direktor Shawn Iadonato am 23.06.2025 237.500 Aktienoptionen zu Ausübungspreisen von 0,36$ und 0,611$ ausgeübt hat. Diese Aktionen wurden durch die vollständige Vesting nach der Zustimmung der Aktionäre zur Fusion mit TuHURA Biosciences ausgelöst.

Zur Deckung der Steuern wurden 52.353 Aktien zum Preis von 0,26$ verkauft (Code F). Nach dem Verkauf stieg sein direkter Aktienbestand auf 860.377 Aktien; zusammen mit 8.553 über ein IRA gehaltenen Aktien beträgt das gesamte wirtschaftliche Eigentum 868.930 Aktien, ein Anstieg von etwa 27%.

Die Transaktionen waren vertraglich bedingt (Code M) und keine Käufe am offenen Markt, was auf eine Übereinstimmung hinweist, jedoch nur begrenzte Einblicke in die Stimmung der Insider bietet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Iadonato Shawn

(Last) (First) (Middle)
C/O KINETA, INC.
7683 SE 27TH STREET, SUITE 481

(Street)
MERCER ISLAND WA 98040

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/23/2025 M 12,500 A $0.611 687,730 D
Common Stock 06/23/2025 M 225,000 A $0.36 912,730 D
Common Stock 06/23/2025 F 52,353 D $0.26 860,377 D
Common Stock 8,553 I By IRA
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.611 06/23/2025 M 12,500 (1) 09/03/2034 Common Stock 12,500 $0 0 D
Stock Option (Right to Buy) $0.36 06/23/2025 M 225,000 (1) 04/13/2034 Common Stock 225,000 $0 0 D
Explanation of Responses:
1. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.
/s/ Nanette Agustines, as Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Kineta (KA) shares did director Shawn Iadonato acquire on 06/23/2025?

He exercised options for 237,500 shares at strike prices of $0.36 and $0.611.

Did Shawn Iadonato sell any Kineta (KA) shares in the latest Form 4?

Yes, 52,353 shares were sold at $0.26 under Code F to cover tax obligations.

What is Shawn Iadonato's total beneficial ownership after the transactions?

The filing shows 868,930 shares owned (860,377 direct; 8,553 indirect via IRA).

Why did the options vest for Kineta’s director on 06/23/2025?

Full vesting was triggered by shareholder approval of the TuHURA Biosciences merger and related Optionholder Treatment Agreement.

What were the exercise prices of the Kineta options exercised?

Options were exercised at $0.36 for 225,000 shares and $0.611 for 12,500 shares.
Kineta, Inc.

NASDAQ:KA

KA Rankings

KA Latest News

KA Latest SEC Filings

KA Stock Data

7.05M
12.26M
34.89%
6%
0.23%
Biotechnology
Pharmaceutical Preparations
Link
United States
MERCER ISLAND